Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers September 28, 2016
Pharmacy Choice - News - U.S. Pharmaceutical Industry - September 28, 2016

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

9/28/16 - Abbott Receives FDA Approval For FreeStyle Libre Pro System
NORTH CHICAGO- Abbott announced the U.S. FDA has approved the company's FreeStyle Libre Pro system, a continuous glucose monitoring system for healthcare professionals to use with their patients with diabetes. The system is designed to empower healthcare professionals to provide better diabetes management for diabetes patients. Abbott recently...
9/28/16 - Abbott Receives FDA Approval for the FreeStyle Libre Pro? System, a Revolutionary Diabetes Sensing Technology for Healthcare Professionals to Use with Their Patients
ABBOTT PARK, Ill., Sept. 28, 2016/ PRNewswire/ Abbott today announced that the U.S. Food and Drug Administration has approved the company's FreeStyle Libre Pro system, a revolutionary continuous glucose monitoring system for healthcare professionals to use with their patients with diabetes. FreeStyle Libre Pro system is designed to empower health
9/28/16 - Abiomed Impella 2.5and Impella 5.0 Heart Pumps Receive Regulatory Approval From Japan Ministry of Health, Labor & Welfare [Arab News (Saudi Arabia)]
-Abiomed, Inc., a leading provider of breakthrough heart support technologies, announced today that the Impella 2.5 and Impella 5.0 heart pumps received Pharmaceuticals and Medical Devices Agency approval from the Japanese Ministry of Health, Labor& Welfare for the treatment of drug-resistant acute heart failure. With this approval, these are the f
9/28/16 - AcelRx Pharmaceuticals Presenting ARX-04 Clinical Trial Findings and Cost Analysis at European Congress on Emergency Medicine
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that the Company and investigators will be presenting two e-posters at the European Congress on Emergency Medicine, which is being held Octobe
9/28/16 - Actinium Announces Initiation of Phase 2 Clinical Trial of Actimab-A in Patients Newly Diagnosed with Acute Myeloid Leukemia Over Age 60 [Daily Tribune (Bahrain)]
-Actinium Pharmaceuticals, Inc., a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has initiated a Phase 2 clinical trial of Actimab-A in patients newly diagnosed with Acute Myeloid Leukemia who are over the age of 60. Actimab-A, Actinium`s m
9/28/16 - Aegerion Pharmaceuticals JUXTAPID (lomitapide) Capsules Approved in Japan for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, today announced that Japan s Ministry of Health, Labor& Welfare has approved JUXTAPID for patients with homozygous familial hypercholesterolemia..
9/28/16 - Aesthetic Lasers Market Is Forecasted To Grow At A CAGR of Around 15.5% By 2024: Hexa Reports
In April 2016, Oculus Innovative Sciences, Inc. received the FDA approval for Microcyn-based Lasercyn Gel, intended for post-non-ablative laser therapy procedures management. The "Global Aesthetic Lasers Market" is expected to reach USD 1.8 billion by 2024, according to a new report by Hexa Reports. For instance, in 2014, Cutera invested USD 10.5 m
9/28/16 - ARIAD Announces Regulatory Approval for Iclusig (ponatinib) in Japan
ARIAD Pharmaceuticals, Inc. today announced that its partner Otsuka Pharmaceutical Co., Ltd. has received approval from the Japanese Pharmaceuticals and Medical Devices Agency for Iclusig for the treatment of chronic myeloid leukemia resistant or intolerant to preceding drug treatment and relapsed or treatment resistant Philadelphia...
9/28/16 - Athersys (ATHX) Receives FDA's Special Protocol Assessment for Phase 3 Study of MultiStem Treatment
Athersys has received an agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the design and planned analysis of a phase 3 clinical trial of the company s novel MultiStem cell therapy product for the treatment of ischemic stroke. Per the SPA agreement, the protocol design, clinical endpoints, planned co
9/28/16 - Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem Treatment for Ischemic Stroke
Athersys, Inc. announced today that it has received agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the design and planned analysis of a Phase 3 clinical trial of Athersys novel MultiStem cell therapy product for the treatment of ischemic stroke. The SPA provides agreement from the FDA that the p
9/28/16 - B2BGateway Provides Fully Integrated EDI Solution for Aptean Ross to Legacy Pharmaceutical Packaging
B2BGateway's cloud based, fully integrated EDI solutions for Aptean Ross were chosen by leading provider of unit-of-use packaging Legacy Pharmaceutical to communicate seamlessly and electronically with customers such as Ascend Laboratories, Kroger and Walmart. Global demand for pharma packaging is expected to grow 6.5% each year to over $100 billio
9/28/16 - Boehringer Ingelheim boosts immune-oncology pipeline through collaboration with ViraTherapeutics
ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic virus therapies, has developed its novel technology with joint support from its lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund and will now be responsible for preclinical and clinical testing of VSV-GP in Phase I trials.
9/28/16 - BRIEF: Senators want to know if EpiPen maker violated law [Star Tribune (Minneapolis)]
Sept. 28 WASHINGTON Several U.S. Senators, including Minnesota Democrat Amy Klobuchar, have asked the Justice Department to determine whether Mylan Pharmaceuticals broke the law in classifying its brand name EpiPen as a generic device in order to lower rebates the company paid to Medicaid. "Pharmaceutical companies are responsible for determin
9/28/16 - Cascadian Therapeutics Announces Poster Presentations on Tucatinib at the European Society of Medical Oncology (ESMO) 2016 Congress
Cascadian Therapeutics, a clinical-stage biopharmaceutical company, today announced two upcoming poster presentations on tucatinib, the Company s lead product candidate for the treatment of HER2+ breast cancer, at the European Society of Medical Oncology 2016 Congress being held October 7 -11, 2016 in Copenhagen, Denmark.. About Cascadian Ther
9/28/16 - Catabasis Pharmaceuticals Announces Closing of $11.5 Million Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional Shares
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the closing of an underwritten offering of 2,875,000 shares of its common stock, including 375,000 shares purchased by the underwriter pursuant to the exercise in full of its option to purchase additional shares, at a price of $4.00 per share. The securities..
9/28/16 - Celltex Clients Address FDA During Two-Day Hearing on Stem Cell Regulation [Daily Star, The (Lebanon)]
-The U.S. Food and Drug Administration has concluded its much-anticipated hearing on the regulation of human cells, tissues and cellular and tissue-based products on September 12-13, 2016, where it received public comment from hundreds of individuals, including three clients of Houston- based biotechnology company Celltex Therapeutics Corporation.
9/28/16 - Cempra Pharmaceuticals Assigned Patent
ALEXANDRIA, Va., Sept. 28 Cempra Pharmaceuticals, Chapel Hill, North Carolina, has been assigned a patent developed by three co-inventors for a "process for the preparation of macrolide antibacterial agents." The co-inventors are David E. Pereira, Apex, North Carolina, Manish Kanchanbhai Patel, Toronto, and Keshav Deo, Vadodara, India. Written by
9/28/16 - Clinical Trial Management System (CTMS) Market worth 1,848.5 Million USD by 2019; Web-based CTMS Solutions in Demand in North America [Qatar Tribune]
-A new Transparency Market Research report states that the global clinical trial management system market was valued at US $844 mn in 2013 and is predicted to reach US $1,848.5 mn by 2019, by expanding at a remarkable CAGR of 14.0% from 2014 to 2019. The title of the report is, Clinical Trial Management System Market- Global Industry Analysis, Size
9/28/16 - Clovis Oncology Announces Rucaparib Data Presentations at ESMO 2016 Congress
Clovis Oncology, Inc. today announced that data from its rucaparib program in ovarian cancer will be presented at the annual European Society for Medical Oncology 2016 Congress. The data being presented comprise the primary efficacy and safety data included in the New Drug Application currently under priority review with the FDA. Rebecca S. Kristel
9/28/16 - DAMAGING INFORMATION: A number of Pharmaceutical Giants And Their Crimes Exposed! [ClickPress (UK)]
For instance, we have Purdue. Novartis is the world's biggest pharmaceutical company by earnings, headquartered in Basel, Switzerland, a 1996 merging in between Ciba-Geigy and Sandoz. Novartis is accountable for lots of medications, from Ritalin to LSD.
9/28/16 - Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress
Dermira, Inc., a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that data from its DRM04 Phase 3 clinical program in patients with primary axillary hyperhidrosis will be presented in a late-breaking
9/28/16 - Drug Distributors Still Benefiting from Drug Price Inflation but Face Major Profit Challenges, Says New Drug Channels Institute Study [Daily News Egypt]
Drug Channels Institutes new 201617 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors reveals how list price increases of brand-name drugs are boosting the industrys revenues, even as changes in the U.S. healthcare system threaten wholesalers profits. We project that U.S. drug distribution revenues at the Big Three public...
9/28/16 - EDITORIAL: No on 61: False promise on drug prices [The Press Democrat, Santa Rosa, Calif.]
Sept. 28 Disgusted with Big Pharma? Proposition 61 would prohibit state agencies from paying more for prescription drugs than the U.S. Department of Veterans Affairs. Federal law guarantees the VA a 24 percent discount below average prices, and, using its muscle as a bulk purchaser, the agency negotiates even lower prices on some commonly used me
9/28/16 - EDITORIAL: No on Prop 61: False promise on drug prices [The Press Democrat, Santa Rosa, Calif.]
Sept. 28 Disgusted with Big Pharma? Proposition 61 would prohibit state agencies from paying more for prescription drugs than the U.S. Department of Veterans Affairs. Federal law guarantees the VA a 24 percent discount below average prices, and, using its muscle as a bulk purchaser, the agency negotiates even lower prices on some commonly used me
9/28/16 - EIP Pharma announces issuance of multiple new patents covering VX-745, a selective p38 MAP kinase alpha inhibitor for Alzheimer's disease and ischemic stroke recovery
EIP Pharma, LLC today announced that the U.S. Patent Office issued on August 30, 2016 the following two patents:. U.S. Patent No. 9,427,438, entitled "Compositions and methods for treating Alzheimer's disease". U.S. Patent No. 8,697,627, with claims directed towards administration of VX-745 to reduce brain amyloid plaque load, was issued to EIP P
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415